US Patent

US7727984 — Medicaments for the treatment of chronic obstructive pulmonary disease

Composition of Matter · Assigned to Boehringer Ingelheim Pharma GmbH and Co KG · Expires 2027-01-19 · 1y remaining

Vulnerability score 27/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a pharmaceutical composition containing the compound olodaterol hydrochloride, used to treat chronic obstructive pulmonary disease.

USPTO Abstract

A pharmaceutical composition comprising a compound of formula 1 wherein: n is 1 or 2; R1 is hydrogen, C1-C4-alkyl, halogen, OH, or —O—C1-C4-alkyl; R2 is hydrogen, C1-C4-alkyl, halogen, OH, or —O—C1-C4-alkyl; R3 is hydrogen, C1-C4-alkyl, OH, halogen, —O—C1-C4-alkyl, —O—C1-C4-alkylene-COOH, or —O—C1-C4-alkylene-CO—O—C1-C4-alkyl, or an acid addition salt thereof with a pharmacologically acceptable acid, or a solvate or hydrate thereof; and a pharmaceutically acceptable excipient or carrier, and methods for using the pharmaceutical formulation in the treatment of chronic obstructive pulmonary disease (COPD).

Drugs covered by this patent

Patent Metadata

Patent number
US7727984
Jurisdiction
US
Classification
Composition of Matter
Expires
2027-01-19
Drug substance claim
Yes
Drug product claim
No
Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.